In Vitro |
RM-018 is a “tricomplex” KRAS inhibitor, which exploits a highly abundant chaperone protein, cyclophilin A, to bind and inhibit KRASG12C[1] .RM-018 (0.01-1000 nM; 72 hours) has an IC50 of 1.4-3.5 nM (KRASG12C) and 2.8-7.3 nM (KRASG12C/Y96D) in NCI-H358, MIA PaCa-2, Ba/F3, and MGH1138-1 cells[1]. RM-018 (0-100 nM; 4 hours) inhibits the expression of KRAS, pERK and pRSK protein[1]. Cell Viability Assay[1] Cell Line: NCI-H358, MIA PaCa-2, Ba/F3, and MGH1138-1 cells, which stably infected with KRASG12C or KRASG12C/Y96D. Concentration: 0.01-1000 nM Incubation Time: 72 hours Result: Inhibited the cell activity, but largely unaffected by KRASG12C/Y96D expression. Western Blot Analysis[1] Cell Line: MIA PaCa-2, HEK293T and MGH1138-1 cells, which expressing KRASG12C or KRASG12C/Y96D. Concentration: 0-100 nM Incubation Time: 4 hours Result: Inhibited KRAS, pERK and pRSK levels with similar potency.
|